When should decision-analytic modeling be used in the economic evaluation of health care? Uwe Siebert MDH, MPH Editorial Pages: 143 - 150
Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998–2001 Josep Darbà Original Papers Pages: 151 - 157
A fuzzy logic approach toward solving the analytic enigma of health system financing Dov ChernichovskyArkady BolotinDavid de Leeuw Original Papers Pages: 158 - 175
Is therapeutic innovation responsible for the increase in drug expenditure? Philippe Cavalié Original Papers Pages: 184 - 194
Costs and effectiveness of a syringe distribution and needle exchange program for HIV prevention in a regional setting Juan M. CabasésEduardo Sánchez Original Papers 01 July 2003 Pages: 203 - 208
Economic evaluation of human papillomavirus screening in Germany T. MittendorfK. U. PetryJ. M. von der Schulenburg Original Papers Pages: 209 - 215
Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK Mike AristidesMichael LeesNikos Maniadakis Original Papers 01 July 2003 Pages: 216 - 221
A single European currency for EQ-5D health states Wolfgang GreinerTom WeijnenFrank de Charro Original papers Pages: 222 - 231
The efficiency of treatment strategies of general practitioners Matthias Staat Congress Papers Pages: 232 - 238
Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials" Jon KarnonA. BrennanJ. Chilcott Commentary Pages: 239 - 240
